BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002;35:552-9. [PMID: 11870367 DOI: 10.1053/jhep.2002.31774] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Yamaguchi K, Whitlock NC, Liggett JL, Legendre AM, Fry MM, Baek SJ. Molecular characterisation of canine nonsteroidal anti-inflammatory drug-activated gene (NAG-1). Vet J 2008;175:89-95. [PMID: 17275371 DOI: 10.1016/j.tvjl.2006.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
2 Gouda AM, Beshr EA, Almalki FA, Halawah HH, Taj BF, Alnafaei AF, Alharazi RS, Kazi WM, AlMatrafi MM. Arylpropionic acid-derived NSAIDs: New insights on derivatization, anticancer activity and potential mechanism of action. Bioorg Chem 2019;92:103224. [PMID: 31491568 DOI: 10.1016/j.bioorg.2019.103224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
3 Giribaldi L, Chiappini F, Pontillo C, Randi AS, Kleiman de Pisarev DL, Alvarez L. Hexachlorobenzene induces deregulation of cellular growth in rat liver. Toxicology 2011;289:19-27. [DOI: 10.1016/j.tox.2011.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
4 Eguchi H, Iwaki K, Shibata K, Ogawa T, Ohta M, Kitano S. Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B. J Hepatobiliary Pancreat Sci 2011;18:147-53. [PMID: 20740367 DOI: 10.1007/s00534-010-0318-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Thompson PA, Khatami M, Baglole CJ, Sun J, Harris SA, Moon EY, Al-Mulla F, Al-Temaimi R, Brown DG, Colacci A, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Amedei A, Hamid RA, Lowe L, Guarnieri T, Bisson WH. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis 2015;36 Suppl 1:S232-53. [PMID: 26106141 DOI: 10.1093/carcin/bgv038] [Cited by in Crossref: 121] [Cited by in F6Publishing: 101] [Article Influence: 17.3] [Reference Citation Analysis]
6 Iwase M, Takaoka S, Uchida M, Kondo G, Watanabe H, Ohashi M, Nagumo M. Accelerative effect of a selective cyclooxygenase-2 inhibitor on Fas-mediated apoptosis in human neutrophils. Int Immunopharmacol 2006;6:334-41. [PMID: 16428068 DOI: 10.1016/j.intimp.2005.08.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
7 Roos J, Grösch S, Werz O, Schröder P, Ziegler S, Fulda S, Paulus P, Urbschat A, Kühn B, Maucher I, Fettel J, Vorup-jensen T, Piesche M, Matrone C, Steinhilber D, Parnham MJ, Maier TJ. Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells? Pharmacology & Therapeutics 2016;157:43-64. [DOI: 10.1016/j.pharmthera.2015.11.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
8 Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010;2010:215158. [PMID: 20339581 DOI: 10.1155/2010/215158] [Cited by in Crossref: 234] [Cited by in F6Publishing: 256] [Article Influence: 19.5] [Reference Citation Analysis]
9 Koustas E, Trifylli EM, Sarantis P, Papavassiliou AG, Karamouzis MV. Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World J Gastrointest Oncol 2021; 13(10): 1229-1243 [PMID: 34721764 DOI: 10.4251/wjgo.v13.i10.1229] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Jung K, Chu K, Lee S, Kim J, Sinn D, Kim J, Park D, Lee J, Kim SU, Kim M, Lee SK, Roh J. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiology of Disease 2006;23:237-46. [DOI: 10.1016/j.nbd.2006.02.016] [Cited by in Crossref: 204] [Cited by in F6Publishing: 206] [Article Influence: 12.8] [Reference Citation Analysis]
11 Maity G, De A, Das A, Banerjee S, Sarkar S, Banerjee SK. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest 2015;95:702-17. [DOI: 10.1038/labinvest.2015.49] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
12 Kwak YE, Jeon NK, Kim J, Lee EJ. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma. Ann N Y Acad Sci 2007;1095:99-112. [PMID: 17404023 DOI: 10.1196/annals.1397.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
13 Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Molecular Cancer Therapeutics 2004;3:299-307. [DOI: 10.1158/1535-7163.299.3.3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
14 Wei MY, Tang ZH, Quan ZW. Intrahepatic cholangiocarcinoma: Role of metabolism in pathogenesis, clinical diagnosis, and treatment. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2929-2937 [DOI: 10.11569/wcjd.v25.i33.2929] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Qu L, Liu B. Cyclooxygeanse-2 promotes metastasis in osteosarcoma. Cancer Cell Int 2015;15:69. [PMID: 26180515 DOI: 10.1186/s12935-015-0220-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
16 Dopp E, von Recklinghausen U, Diaz-Bone R, Hirner AV, Rettenmeier AW. Cellular uptake, subcellular distribution and toxicity of arsenic compounds in methylating and non-methylating cells. Environ Res. 2010;110:435-442. [PMID: 19758587 DOI: 10.1016/j.envres.2009.08.012] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 5.2] [Reference Citation Analysis]
17 Liu R, Li X, Qiang X, Luo L, Hylemon PB, Jiang Z, Zhang L, Zhou H. Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line. J Biol Chem. 2015;290:30988-31002. [PMID: 26518876 DOI: 10.1074/jbc.m115.668277] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
18 Chakraborty H, Grihanjali Devi P, Sarkar M, Dasgupta D. New Functions of Old Drugs: Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs. Recent Advances in Medicinal Chemistry. Elsevier; 2014. pp. 3-55. [DOI: 10.1016/b978-0-12-803961-8.50001-4] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004;39:1028-37. [PMID: 15057907 DOI: 10.1002/hep.20143] [Cited by in Crossref: 83] [Cited by in F6Publishing: 117] [Article Influence: 4.6] [Reference Citation Analysis]
20 Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 2004;39:732-8. [PMID: 14999691 DOI: 10.1002/hep.20125] [Cited by in Crossref: 64] [Cited by in F6Publishing: 109] [Article Influence: 3.6] [Reference Citation Analysis]
21 Núñez Martínez O, Clemente Ricote G, García Monzón C. [Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases]. Med Clin (Barc) 2003;121:743-8. [PMID: 14678698 DOI: 10.1016/s0025-7753(03)74082-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
22 Liu B, Qu L, Yang Z, Tao H. Cyclooxygenase-2 inhibitors induce anoikis in osteosarcoma via PI3K/Akt pathway. Med Hypotheses 2012;79:98-100. [PMID: 22546756 DOI: 10.1016/j.mehy.2012.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
23 Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol 2010; 2(3): 136-145 [PMID: 21160821 DOI: 10.4251/wjgo.v2.i3.136] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
24 Suzuki S, Hashizume K. Do PPARgamma Ligands Suppress the Growth of Cholangiocarcinoma or the Cholangiohepatitis Induced by the Tumor? PPAR Res 2008;2008:587401. [PMID: 18615198 DOI: 10.1155/2008/587401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
25 Foster J, Black J, LeVea C, Khoury T, Kuvshinoff B, Javle M, Gibbs JF. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol. 2007;14:752-758. [PMID: 17146741 DOI: 10.1245/s10434-006-9123-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
26 Mott JL, Gores GJ. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology 2007;46:906-11. [PMID: 17654739 DOI: 10.1002/hep.21812] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
27 Liu B, Yan S, Qu L, Zhu J. Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway. Cancer Cell Int 2017;17:1. [PMID: 28053596 DOI: 10.1186/s12935-016-0378-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
28 Abu El-asrar AM, Dralands L, Missotten L, Geboes K. Expression of antiapoptotic and proapoptotic molecules in diabetic retinas. Eye 2007;21:238-45. [DOI: 10.1038/sj.eye.6702225] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
29 Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 2004;41:808-814. [PMID: 15519654 DOI: 10.1016/j.jhep.2004.07.016] [Cited by in Crossref: 87] [Cited by in F6Publishing: 136] [Article Influence: 5.1] [Reference Citation Analysis]
30 Agarwal S, Reddy GV, Reddanna P. Eicosanoids in inflammation and cancer: the role of COX-2. Expert Rev Clin Immunol 2009;5:145-65. [PMID: 20477063 DOI: 10.1586/1744666X.5.2.145] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
31 Subongkot S, Frame D, Leslie W, Drajer D. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy. 2003;23:9-28. [PMID: 12523457 DOI: 10.1592/phco.] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
32 McCarty MF, Block KI. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. Integr Cancer Ther 2006;5:252-68. [PMID: 16880431 DOI: 10.1177/1534735406291499] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
33 Maroni L, Pierantonelli I, Banales JM, Benedetti A, Marzioni M. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1:28. [PMID: 25332972 DOI: 10.3978/j.issn.2305-5839.2012.10.04] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
34 Ishaque A, Dunn MJ, Sorokin A. Cyclooxygenase-2 inhibits tumor necrosis factor alpha-mediated apoptosis in renal glomerular mesangial cells. J Biol Chem 2003;278:10629-40. [PMID: 12511556 DOI: 10.1074/jbc.M210559200] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
35 Kataoka K, Takikawa Y, Lin SD, Suzuki K. Prostaglandin E2 receptor EP4 agonist induces Bcl-xL and independently activates proliferation signals in mouse primary hepatocytes. J Gastroenterol 2005;40:610-6. [DOI: 10.1007/s00535-005-1595-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
36 Wentz SC, Yip-schneider MT, Gage EA, Saxena R, Badve S, Schmidt CM. Sulindac Prevents Carcinogen-Induced Intrahepatic Cholangiocarcinoma Formation In Vivo. Journal of Surgical Research 2009;157:e87-95. [DOI: 10.1016/j.jss.2008.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
37 Kim YJ, Choi MH, Hong ST, Bae YM. Resistance of cholangiocarcinoma cells to parthenolide-induced apoptosis by the excretory-secretory products of Clonorchis sinensis. Parasitol Res 2009;104:1011-6. [PMID: 19066964 DOI: 10.1007/s00436-008-1283-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
38 Oh K, Lee S, Choi H, Oh D, Kim S, Min DS, Kim JM, Lee KS, Han J. Role of phospholipase D2 in anti-apoptotic signaling through increased expressions of Bcl-2 and Bcl-xL. J Cell Biochem 2007;101:1409-22. [DOI: 10.1002/jcb.21260] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
39 Verdina A, Cardillo I, Nebbioso A, Galati R, Menegozzo S, Altucci L, Sacchi A, Baldi A. Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. J Transl Med 2008;6:27. [PMID: 18498639 DOI: 10.1186/1479-5876-6-27] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
40 Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005;41:5-15. [PMID: 15690474 DOI: 10.1002/hep.20537] [Cited by in Crossref: 225] [Cited by in F6Publishing: 226] [Article Influence: 13.2] [Reference Citation Analysis]
41 Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, Ullmer C, Knoefel WT, Herebian D, Mayatepek E, Häussinger D, Keitel V. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut 2016;65:487-501. [PMID: 26420419 DOI: 10.1136/gutjnl-2015-309458] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 18.2] [Reference Citation Analysis]
42 Compare D, Nardone O, Nardone G. Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract. Pharmaceuticals (Basel) 2010;3:2495-516. [PMID: 27713364 DOI: 10.3390/ph3082495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
43 Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005;280:24053-63. [PMID: 15855163 DOI: 10.1074/jbc.M500562200] [Cited by in Crossref: 114] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
44 Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun Rev 2003;2:36-42. [PMID: 12848974 DOI: 10.1016/s1568-9972(02)00125-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
45 Ribeiro CCD, Silva RM, Campanholo VMLP, Ribeiro DA, Ribeiro Paiotti AP, Forones NM. Effects of Grape Juice in Superoxide Dismutase and Catalase in Colorectal Cancer Carcinogenesis Induced by Azoxymethane. Asian Pac J Cancer Prev 2018;19:2839-44. [PMID: 30362310 DOI: 10.22034/APJCP.2018.19.10.2839] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Zhang M, Xu Z, Shi Z, Shao D, Li O, Li W, Li Z, Wang K, Chen L. Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A2 and peroxisome proliferator-activated receptor gamma. Mol Cell Biochem 2011;355:233-40. [DOI: 10.1007/s11010-011-0859-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
47 Lu D, Han C, Wu T. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Gastroenterology 2011;140:2084-94. [PMID: 21354147 DOI: 10.1053/j.gastro.2011.02.056] [Cited by in Crossref: 18] [Cited by in F6Publishing: 63] [Article Influence: 1.6] [Reference Citation Analysis]
48 Inoue T, Anai S, Onishi S, Miyake M, Tanaka N, Hirayama A, Fujimoto K, Hirao Y. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol 2013;13:1. [PMID: 23289871 DOI: 10.1186/1471-2490-13-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
49 Yang P, Zhang Y, Ping L, Gao X. Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: Molecular mechanisms and therapeutic potential. International Immunopharmacology 2007;7:1414-21. [DOI: 10.1016/j.intimp.2007.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
50 Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A. Chemosensitization of Pancreatic Carcinoma Cells to Enhance T Cell-Mediated Cytotoxicity Induced by Tumor Lysate-Pulsed Dendritic Cells. Journal of Immunotherapy 2005;28:332-42. [DOI: 10.1097/01.cji.0000164038.41104.f5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
51 Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol 2006;1:9. [PMID: 16722607 DOI: 10.1186/1748-717X-1-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
52 Huang Y, Hung W, Kang W, Chen W, Chai C. p-Phenylenediamine induced DNA damage in SV-40 immortalized human uroepithelial cells and expression of mutant p53 and COX-2 proteins. Toxicology Letters 2007;170:116-23. [DOI: 10.1016/j.toxlet.2007.02.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
53 Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Na HK, Kim JW, Surh YJ, Bang YJ, Song YS. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol. 2004;130:551-560. [PMID: 15197583 DOI: 10.1007/s00432-004-0567-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.0] [Reference Citation Analysis]
54 Yao C, Li G, Cai M, Qian Y, Wang L, Xiao L, Thaiss F, Shi B. Prostate cancer downregulated SIRP-α modulates apoptosis and proliferation through p38-MAPK/NF-κB/COX-2 signaling. Oncol Lett 2017;13:4995-5001. [PMID: 28588738 DOI: 10.3892/ol.2017.6070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
55 Tsuchida A, Itoi T, Kasuya K, Endo M, Katsumata K, Aoki T, Suzuki M, Aoki T. Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters. Carcinogenesis 2005;26:1922-8. [PMID: 15944215 DOI: 10.1093/carcin/bgi149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
56 Sano T, Ozaki K, Kodama Y, Matsuura T, Narama I. Paradoxical effects of a selective cyclooxygenase-2 inhibitor, etodolac, on proliferative changes of forestomach in alloxan-induced diabetic rats. Experimental and Toxicologic Pathology 2009;61:371-80. [DOI: 10.1016/j.etp.2008.10.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
57 Perez-Montoyo H. Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma. Cells 2020;9:E614. [PMID: 32143356 DOI: 10.3390/cells9030614] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
58 Han C, Demetris AJ, Stolz DB, Xu L, Lim K, Wu T. Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. J Biol Chem. 2006;281:24831-24846. [PMID: 16790433 DOI: 10.1074/jbc.m602201200] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
59 Cheng AS, Chan HL, Leung WK, To KF, Go MY, Chan JY, Liew CT, Sung JJ. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2004;17:1169-79. [PMID: 15218507 DOI: 10.1038/modpathol.3800196] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 3.9] [Reference Citation Analysis]
60 [DOI: 10.1101/518340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Xu L, Han C, Wu T. A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J Biol Chem 2006;281:33982-96. [PMID: 16966336 DOI: 10.1074/jbc.M600135200] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
62 Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer. 2003;2:10. [PMID: 12575899 DOI: 10.1186/1476-4598-2-10] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 4.7] [Reference Citation Analysis]
63 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21. [PMID: 18536057 DOI: 10.1002/hep.22310] [Cited by in Crossref: 492] [Cited by in F6Publishing: 461] [Article Influence: 35.1] [Reference Citation Analysis]
64 Fava G, Lorenzini I. Molecular pathogenesis of cholangiocarcinoma. Int J Hepatol 2012;2012:630543. [PMID: 21994887 DOI: 10.1155/2012/630543] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
65 Yao L, Han C, Song K, Zhang J, Lim K, Wu T. Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res 2015;75:1388-98. [PMID: 25691459 DOI: 10.1158/0008-5472.CAN-14-2561] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
66 Chen LH, Liu XS, Wang WY, Han WN, Pan BR, Jin BQ. Localization of TRAIL/TRAILR in fetal pancreas. World J Gastroenterol 2003; 9(2): 334-337 [PMID: 12532461 DOI: 10.3748/wjg.v9.i2.334] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
67 Gores GJ. Cholangiocarcinoma: preventing invasion as anti-cancer strategy. J Hepatol 2003;38:671-3. [PMID: 12713880 DOI: 10.1016/s0168-8278(03)00125-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
68 Ren H, Chen X, Jiang F, Li G. Cyclooxygenase-2 Inhibition Reduces Autophagy of Macrophages Enhancing Extraintestinal Pathogenic Escherichia coli Infection. Front Microbiol 2020;11:708. [PMID: 32362888 DOI: 10.3389/fmicb.2020.00708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Wang WY, Tang HW, Zhang ZP, Han B, Gao YH, Ma FC, Yan QG, Zhao YL. Expression of Bag-1 and Bcl-2 and its significance in gastric cancer. Shijie Huaren Xiaohua Zazhi 2005; 13(10): 1186-1189 [DOI: 10.11569/wcjd.v13.i10.1186] [Reference Citation Analysis]
70 Kuttler B, Steveling A, Klöting N, Morgenstern O, Wanka H. Aminoguanidine downregulates expression of cytokine-induced Fas and inducible nitric oxide synthase but not cytokine-enhanced surface antigens of rat islet cells. Biochemical Pharmacology 2003;66:2437-48. [DOI: 10.1016/j.bcp.2003.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
71 Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98:736-747. [PMID: 16757698 DOI: 10.1093/jnci/djj206] [Cited by in Crossref: 349] [Cited by in F6Publishing: 306] [Article Influence: 21.8] [Reference Citation Analysis]
72 Wehbi VL, Taskén K. Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units. Front Immunol 2016;7:222. [PMID: 27375620 DOI: 10.3389/fimmu.2016.00222] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 13.7] [Reference Citation Analysis]
73 Yu Y, Liu Q, Guo S, Zhang Q, Tang J, Liu G, Kong D, Li J, Yan S, Wang R, Wang P, Su X, Yu Y. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin promotes endothelial cell apoptosis through activation of EP3/p38MAPK/Bcl-2 pathway. J Cell Mol Med 2017;21:3540-51. [PMID: 28699682 DOI: 10.1111/jcmm.13265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
74 Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15:106. [PMID: 26549987 DOI: 10.1186/s12935-015-0260-7] [Cited by in Crossref: 140] [Cited by in F6Publishing: 146] [Article Influence: 20.0] [Reference Citation Analysis]
75 Tsubouchi H. Sustained activation of epidermal growth factor receptor in cholangiocarcinoma: a potent therapeutic target? J Hepatol. 2004;41:859-861. [PMID: 15519661 DOI: 10.1016/j.jhep.2004.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
76 Zhu F, Wang P, Lee NH, Goldring MB, Konstantopoulos K. Prolonged application of high fluid shear to chondrocytes recapitulates gene expression profiles associated with osteoarthritis. PLoS One 2010;5:e15174. [PMID: 21209926 DOI: 10.1371/journal.pone.0015174] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
77 Fava G, Marzioni M, Benedetti A, Glaser S, DeMorrow S, Francis H, Alpini G. Molecular pathology of biliary tract cancers. Cancer Lett. 2007;250:155-167. [PMID: 17069969 DOI: 10.1016/j.canlet.2006.09.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
78 Sano T, Ozaki K, Kodama Y, Matsuura T, Narama I. Prevention of proliferative changes of forestomach mucosa by blood glucose control with insulin in alloxan-induced diabetic rats. Cancer Science 2009;100:595-600. [DOI: 10.1111/j.1349-7006.2008.01081.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
79 Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta. 2005;1755:135-150. [PMID: 15921858 DOI: org/10.1016/j.bbcan.2005.04.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Li Y, Niu Y, Wu H, Zhang B, Sun Y, Huang H, Li Q, Fan L, Liu L, Mei Q. PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo. Cancer Science 2009;100:2451-8. [DOI: 10.1111/j.1349-7006.2009.01335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
81 Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D. Cholangiocarcinoma: Update and future perspectives. Digestive and Liver Disease 2010;42:253-60. [DOI: 10.1016/j.dld.2009.12.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 10.3] [Reference Citation Analysis]
82 Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005;54:1024-33. [PMID: 15951554 DOI: 10.1136/gut.2004.053850] [Cited by in Crossref: 327] [Cited by in F6Publishing: 315] [Article Influence: 19.2] [Reference Citation Analysis]
83 Negi AK, Kansal S, Bhatnagar A, Agnihotri N. Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis. Tumor Biol 2013;34:3753-64. [DOI: 10.1007/s13277-013-0959-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
84 Totzke G, Schulze-Osthoff K, Jänicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene. 2003;22:8021-8030. [PMID: 12970750 DOI: 10.1038/sj.onc.1206837] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
85 Tjiu JW, Liao YH, Lin SJ, Huang YL, Tsai WL, Chu CY, Kuo ML, Jee SH. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol. 2006;126:1143-1151. [PMID: 16528365 DOI: 10.1038/sj.jid.5700191] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
86 Yan QG, Shi JG, Huang GS, Zhang CS, Li Q, Hu PZ, Wang WL. In situ quantitative study of BAG-1 and BAD in extrahepatic cholangiocarcinoma. Shijie Huaren Xiaohua Zazhi 2003; 11(8): 1144-1147 [DOI: 10.11569/wcjd.v11.i8.1144] [Reference Citation Analysis]
87 Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A. Cyclooxygenase-2 expression in thyroid neoplasms: Cox-2 in thyroid carcinoma. Histopathology 2003;42:492-7. [DOI: 10.1046/j.1365-2559.2003.01624.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
88 Müller R. Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol 2004;130:429-44. [PMID: 15205946 DOI: 10.1007/s00432-004-0570-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
89 Fecker LF, Stockfleth E, Braun FK, Rodust PM, Schwarz C, Köhler A, Leverkus M, Eberle J. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol 2010;130:2098-109. [PMID: 20237495 DOI: 10.1038/jid.2010.40] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
90 Hakozaki M, Tajino T, Konno S, Kikuchi S, Yamada H, Yanagisawa M, Nishida J, Nagasawa H, Tsuchiya T, Ogose A, Abe M, Hojo H. Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells. PLoS One 2014;9:e88035. [PMID: 24516579 DOI: 10.1371/journal.pone.0088035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
91 Park JW, Park JE, Lee JA, Lee CW, Kim CM. Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol. 2006;132:184-192. [PMID: 16331492 DOI: 10.1007/s00432-005-0060-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
92 Negi AK, Renuka, Bhatnagar A, Agnihotri N. Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer. Inflammopharmacology 2016;24:11-22. [PMID: 26749133 DOI: 10.1007/s10787-015-0259-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
93 Jang TJ, Kim NI, Lee CH. Proapoptotic activity of NAG-1 is cell type specific and not related to COX-2 expression. Apoptosis. 2006;11:1131-1138. [PMID: 16699947 DOI: 10.1007/s10495-006-8160-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
94 Liu W, Zhang L, Xu HJ, Li Y, Hu CM, Yang JY, Sun MY. The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis. Int J Mol Sci 2018;19:E2736. [PMID: 30216977 DOI: 10.3390/ijms19092736] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
95 Chen Y, Xu J, Jhala N, Pawar P, Zhu ZB, Ma L, Byon CH, McDonald JM. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006;169:1833-42. [PMID: 17071604 DOI: 10.2353/ajpath.2006.060234] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
96 Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol. 2007;61:44-51. [PMID: 17164111 DOI: 10.1016/j.critrevonc.2006.07.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
97 Anand P, Filipenko P, Huaman J, Lyudmer M, Hossain M, Santamaria C, Huang K, Ogunwobi OO, Holford M. Selective Inhibition of Liver Cancer Cells Using Venom Peptide. Mar Drugs 2019;17:E587. [PMID: 31627357 DOI: 10.3390/md17100587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
98 Liu JW, Li KZ, Dou KF, Song ZS, Su MQ, Yu WB. Effects of COX-2 inhibitor with cisplatin on proliferation and apoptosis of pancreatic cancer cells. Shijie Huaren Xiaohua Zazhi 2004; 12(5): 1139-1143 [DOI: 10.11569/wcjd.v12.i5.1139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Koga H. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer. 2003;98:661-667. [PMID: 12910508 DOI: 10.1002/cncr.11576] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
100 El-Awady RA, Saleh EM, Ezz M, Elsayed AM. Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells. Toxicol Appl Pharmacol. 2011;255:271-286. [PMID: 21763710 DOI: 10.1016/j.taap.2011.06.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
101 Shaji S, Smith C, Forget P. Perioperative NSAIDs and Long-Term Outcomes After cancer Surgery: a Systematic Review and Meta-analysis. Curr Oncol Rep 2021;23:146. [PMID: 34748112 DOI: 10.1007/s11912-021-01133-8] [Reference Citation Analysis]